Alpha Tau Medical Ltd.

NasdaqCM DRTS

Alpha Tau Medical Ltd. Debt to Equity Ratio for the year ending December 31, 2023: 0.16

Alpha Tau Medical Ltd. Debt to Equity Ratio is 0.16 for the year ending December 31, 2023, a 219.76% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.

Alpha Tau Medical Ltd. Debt to Equity Ratio for the year ending December 31, 2022 was 0.05.
Alpha Tau Medical Ltd. Debt to Equity Ratio for the year ending December 31, 2020 was -6.40.

Key data

Date	Debt to Equity Ratio	Debt to Income Ratio	Debt to Tangible Net Worth Ratio	Dividend Coverage Ratio

NasdaqCM: DRTS

Alpha Tau Medical Ltd.

CEO	Mr. Uzi Sofer
IPO Date	March 8, 2021
Location	Israel
Headquarters	5 Kiryat Hamada Street
Employees	121
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Pharmaceuticals

Description

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.

Key trends

Past 5 years